Figure 1. (Thorlund et al.)

Effect of Anti-TNF Therapy on the Occurrence of Malignancies in Randomized Controlled Trials

Peto Odds Ratio (fixed-effect)
- Adalimumab
- Etanercept
- Infliximab

Overall

Mantel-Haenszel Odds Ratio (fixed-effect)
- Adalimumab
- Etanercept
- Infliximab

Overall

Mantel-Haenszel Odds Ratio (random-effect)
- Adalimumab
- Etanercept
- Infliximab

Overall

Inverse-variance Odds Ratio (fixed-effect)
- Adalimumab
- Etanercept
- Infliximab

Overall

Inverse-variance Odds Ratio (random-effect)
- Adalimumab
- Etanercept
- Infliximab

Overall

GLIMMIX Odds Ratio (random-effect; incl. all data)
- Adalimumab
- Etanercept
- Infliximab

Overall

GLIMMIX Odds Ratio (random-effect; excl. zero-zero events data)
- Adalimumab
- Etanercept
- Infliximab

Overall

WinBUGS Odds Ratio (fixed-effect)
Overall: OR = 2.81 (1.44 to 5.91)

WinBUGS Odds Ratio (random-effect)
Overall: OR = 3.22 (1.49 to 11.07)